<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01429285</url>
  </required_header>
  <id_info>
    <org_study_id>MMC 08-11-387</org_study_id>
    <nct_id>NCT01429285</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Intravenous Hydromorphone in Elderly Emergency Department Patients With Acute Severe Pain</brief_title>
  <official_title>Safety and Efficacy of Intravenous Hydromorphone Using Incremental Doses of 0.5 mg in Elderly ED Patients With Acute Severe Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hydromorphone protocol is more effective than usual care in Emergency Department (ED)
      patients age 65 years and older in terms of proportion who choose to forgo additional pain
      medication within 60 minutes post-baseline in the two groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Successful Treatment</measure>
    <time_frame>1 hour</time_frame>
    <description>Number of patients with &quot;successful treatment&quot; is defined as the number of patients who declined additional pain medication within 1 hour of study entry when asked the question, &quot;Do you want more pain medication?&quot;. This measure looks at declining pain medication at either 15 minutes or 60 minutes, whereas 4. Post-Hoc refers only to the answer to the question at the 60 minute mark post-baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Pain Intensity From Baseline to 60 Minutes</measure>
    <time_frame>60 minutes</time_frame>
    <description>Pain intensity is measured on the numerical rating scale (NRS) with scores ranging from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain imaginable&quot;). The change in scores over time is calculated by subtracting the score at 60 minutes from the score at baseline (before treatment). These change values were then averaged.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Hydromorphone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydromorphone protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone</intervention_name>
    <description>0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose</description>
    <arm_group_label>Hydromorphone</arm_group_label>
    <other_name>Dilaudid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Attending administers any IV opioid in any dose he chooses</description>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age greater than or equal to 65 years: This is a study of elderly patients.

          2. Pain with onset within 7 days: Pain within seven days is the definition of acute pain
             that has been used in Emergency Department (ED) literature.

          3. ED attending physician's judgment that patient's pain may warrant intravenous (IV)
             opioids: The factors that influence the decision to use parenteral opioids are complex
             and extensive. An approach that is commonly taken to address the issue of patient
             selection in drug trials is to use a specific condition (e.g., renal colic) or
             treatment (e.g., post-hysterectomy) that would generally be thought to be
             appropriately treated with an opioid analgesic, thereby eliminating individual
             judgment about eligibility for the study. However in order to assess the role of
             opioids with the widest generalizability in the ED setting, the investigators decided
             to enroll patients with a variety of diagnoses, all with a complaint of acute pain.
             Opioids are not an appropriate treatment for all patients who present with a complaint
             of pain (e.g., gastroenteritis, migraine). Therefore, unless there is a restriction to
             patients with a specific diagnosis, either a comprehensive list of diagnoses and
             situations in which opioids are indicated must be specified, or clinical judgment
             needs to be used. The investigators have opted for the latter alternative.

          4. Normal mental status: In order to provide measures of pain experienced the patient
             needs to have a normal mental status. The investigators will use a 6-item screener
             (Wilber 2008) as an indicator of sufficiently normal mental status to participate in
             the study.

        Exclusion Criteria:

          1. Prior use of methadone: the effect of methadone use on the perception of acute pain is
             unknown and suspected to be altered. The investigators feel that the needs of patients
             on methadone may exceed the dosage ceiling of 1 mg that will be used for this study.
             Similar to sickle cell patients and chronic cancer patients, patients on methadone
             usually require significantly higher doses of opioids to control their pain. Thus, the
             investigators feel that it would be unethical to restrict the dose that this subset of
             patients can receive.

          2. Use of other opioids or tramadol within past seven days: to avoid introducing bias
             related to opioid tolerance that may alter the response to the study medication
             thereby masking the medication's effect.

          3. Prior adverse reaction to opioids.

          4. Chronic pain syndrome: frequently recurrent or daily pain for at least 3 months
             results in alteration in pain perception which is thought to be due to down-regulation
             of pain receptors. Examples of chronic pain syndromes include sickle cell anemia,
             osteoarthritis, fibromyalgia, migraine, and peripheral neuropathies.

          5. Alcohol intoxication: the presence of alcohol intoxication as judged by the treating
             physician may alter perception, report, and treatment of pain.

          6. Systolic blood pressure &lt;90 mm Hg: Opioids can produce peripheral vasodilation that
             may result in orthostatic hypotension.

          7. Oxygen saturation &lt;95% on room air: For this study, oxygen saturation must be 95% or
             above on room air in order to be enrolled.

          8. Use of monoamine oxidase (MAO) inhibitors in past 30 days: MAO inhibitors have been
             reported to intensify the effects of at least one opioid drug causing anxiety,
             confusion and significant respiratory depression or coma.

          9. C02 measurement greater than 46: In accordance with a similar study (04-12-360), three
             subsets of patients will have their CO2 measured using a handheld capnometer prior to
             enrollment in the study. If the CO2 measurement is greater than 46, then the patient
             will be excluded from the study. The 3 subsets are as follows:

               -  All patients who have a history of chronic obstructive pulmonary disease (COPD)

               -  All patients who report a history of asthma together with greater than a 20
                  pack-year smoking history

               -  All patients reporting less than a 20 pack-year smoking history who are having an
                  asthma exacerbation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Montefiore Emergency Department</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2011</study_first_submitted>
  <study_first_submitted_qc>September 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2011</study_first_posted>
  <results_first_submitted>February 9, 2018</results_first_submitted>
  <results_first_submitted_qc>March 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2018</results_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Andrew Chang, MD</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Hydromorphone</keyword>
  <keyword>Acute</keyword>
  <keyword>Emergency Department</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hydromorphone</title>
          <description>Hydromorphone protocol
Hydromorphone: 0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>Usual care
Usual care: Attending administers any IV opioid in any dose he chooses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Given IV Opioids</title>
              <participants_list>
                <participants group_id="P1" count="166">9 patients never given IV opioids</participants>
                <participants group_id="P2" count="171">4 patients never given IV opioids</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Primary Outcome Data</title>
              <participants_list>
                <participants group_id="P1" count="161">5 patients had missing data</participants>
                <participants group_id="P2" count="168">3 patients had missing data</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Confirmation of no Duplicate Enrollment</title>
              <participants_list>
                <participants group_id="P1" count="153">8 patients were enrolled twice at two separate ED visits, which was only noted at study conclusion.</participants>
                <participants group_id="P2" count="166">2 patients were enrolled twice, at two separate ED visits, which was only noted at study conclusion</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing Data</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Erroneously Enrolled Twice</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hydromorphone</title>
          <description>Hydromorphone protocol
Hydromorphone: 0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose</description>
        </group>
        <group group_id="B2">
          <title>Usual Care</title>
          <description>Usual care
Usual care: Attending administers any IV opioid in any dose he chooses</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="153"/>
            <count group_id="B2" value="166"/>
            <count group_id="B3" value="319"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75" spread="7"/>
                    <measurement group_id="B2" value="74" spread="6"/>
                    <measurement group_id="B3" value="74" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="213"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162" spread="33"/>
                    <measurement group_id="B2" value="165" spread="38"/>
                    <measurement group_id="B3" value="164" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Non-specific abdominal pain</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Musculoskeletal pain</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Back pain</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Colitis/diverticulitis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Small Bowel Obstruction</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extremity fracture</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>biliary colic/cholecystitis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Kidney stone/pyelonephritis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Appendicitis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other (pancreatitis, perforated viscus, etc)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain Intensity</title>
          <description>Pain intensity is measured on the numerical rating scale (NRS), with scores ranging from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain imaginable&quot;).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>NRS = 3-6</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NRS = 7</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NRS = 8</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NRS = 9</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NRS = 10</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nauseated or vomited before receiving opioids in the ED</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="176"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Successful Treatment</title>
        <description>Number of patients with &quot;successful treatment&quot; is defined as the number of patients who declined additional pain medication within 1 hour of study entry when asked the question, &quot;Do you want more pain medication?&quot;. This measure looks at declining pain medication at either 15 minutes or 60 minutes, whereas 4. Post-Hoc refers only to the answer to the question at the 60 minute mark post-baseline.</description>
        <time_frame>1 hour</time_frame>
        <population>The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8)</population>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>Hydromorphone protocol
Hydromorphone: 0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual care
Usual care: Attending administers any IV opioid in any dose he chooses</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Successful Treatment</title>
          <description>Number of patients with &quot;successful treatment&quot; is defined as the number of patients who declined additional pain medication within 1 hour of study entry when asked the question, &quot;Do you want more pain medication?&quot;. This measure looks at declining pain medication at either 15 minutes or 60 minutes, whereas 4. Post-Hoc refers only to the answer to the question at the 60 minute mark post-baseline.</description>
          <population>The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Achieved satisfactory analgesia within 60 min</title>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="137"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No satisfactory analgesia within 60 min</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Pain Intensity From Baseline to 60 Minutes</title>
        <description>Pain intensity is measured on the numerical rating scale (NRS) with scores ranging from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain imaginable&quot;). The change in scores over time is calculated by subtracting the score at 60 minutes from the score at baseline (before treatment). These change values were then averaged.</description>
        <time_frame>60 minutes</time_frame>
        <population>The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8)</population>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>Hydromorphone protocol
Hydromorphone: 0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual care
Usual care: Attending administers any IV opioid in any dose he chooses</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Pain Intensity From Baseline to 60 Minutes</title>
          <description>Pain intensity is measured on the numerical rating scale (NRS) with scores ranging from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain imaginable&quot;). The change in scores over time is calculated by subtracting the score at 60 minutes from the score at baseline (before treatment). These change values were then averaged.</description>
          <population>The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="2.9"/>
                    <measurement group_id="O2" value="5.2" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Patients Who Achieved Satisfactory Analgesia at 15 Minutes Post-baseline</title>
        <description>Satisfactory Analgesia is defined as declining additional pain medication when asked the question, &quot;Do you want more pain medication?&quot;</description>
        <time_frame>15 minutes</time_frame>
        <population>The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8)</population>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>Hydromorphone protocol
Hydromorphone: 0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual care
Usual care: Attending administers any IV opioid in any dose he chooses</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Achieved Satisfactory Analgesia at 15 Minutes Post-baseline</title>
          <description>Satisfactory Analgesia is defined as declining additional pain medication when asked the question, &quot;Do you want more pain medication?&quot;</description>
          <population>The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Patients Who Achieved Satisfactory Analgesia at 60 Minutes Post-baseline</title>
        <description>&quot;Satisfactory analgesia&quot; is defined as the patient declining additional pain medication when asked the question, &quot;Do you want more pain medication?&quot;. This measure refers only to the answer to this question asked at the 60 minute mark. The Primary Outcome (1. Primary Outcome - Number of Patients with successful treatment) refers to the answering &quot;no&quot; to this question at 15 minutes or 60 minutes post-baseline.</description>
        <time_frame>60 minutes</time_frame>
        <population>The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8)</population>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>Hydromorphone protocol
Hydromorphone: 0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual care
Usual care: Attending administers any IV opioid in any dose he chooses</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Achieved Satisfactory Analgesia at 60 Minutes Post-baseline</title>
          <description>&quot;Satisfactory analgesia&quot; is defined as the patient declining additional pain medication when asked the question, &quot;Do you want more pain medication?&quot;. This measure refers only to the answer to this question asked at the 60 minute mark. The Primary Outcome (1. Primary Outcome - Number of Patients with successful treatment) refers to the answering &quot;no&quot; to this question at 15 minutes or 60 minutes post-baseline.</description>
          <population>The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Patients With 50% or Greater Decline in Pain Intensity Score From Baseline to 60 Minutes</title>
        <description>Pain intensity is measured on the numerical rating scale (NRS) with scores ranging from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain imaginable&quot;). The 50% or greater change in pain score is measured by subtracting the pain score at 60 minutes from the pain score at baseline, then dividing that value by the original baseline value and multiplying by 100% to get a percent change value.</description>
        <time_frame>60 minutes</time_frame>
        <population>The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8)</population>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>Hydromorphone protocol
Hydromorphone: 0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual care
Usual care: Attending administers any IV opioid in any dose he chooses</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With 50% or Greater Decline in Pain Intensity Score From Baseline to 60 Minutes</title>
          <description>Pain intensity is measured on the numerical rating scale (NRS) with scores ranging from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain imaginable&quot;). The 50% or greater change in pain score is measured by subtracting the pain score at 60 minutes from the pain score at baseline, then dividing that value by the original baseline value and multiplying by 100% to get a percent change value.</description>
          <population>The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Patients With a Pain Intensity Score of 3 or Less at 60 Minutes</title>
        <description>Pain intensity is measured on the numerical rating scale (NRS) with scores ranging from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain imaginable&quot;).</description>
        <time_frame>60 minutes</time_frame>
        <population>The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8)</population>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>Hydromorphone protocol
Hydromorphone: 0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual care
Usual care: Attending administers any IV opioid in any dose he chooses</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a Pain Intensity Score of 3 or Less at 60 Minutes</title>
          <description>Pain intensity is measured on the numerical rating scale (NRS) with scores ranging from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain imaginable&quot;).</description>
          <population>The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Pain Intensity Score at 60 Minutes</title>
        <description>Pain intensity is measured on the numerical rating scale (NRS) with scores ranging from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain imaginable&quot;).</description>
        <time_frame>60 minutes</time_frame>
        <population>The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8)</population>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>Hydromorphone protocol
Hydromorphone: 0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual care
Usual care: Attending administers any IV opioid in any dose he chooses</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Score at 60 Minutes</title>
          <description>Pain intensity is measured on the numerical rating scale (NRS) with scores ranging from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain imaginable&quot;).</description>
          <population>The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8)</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 minutes</time_frame>
      <desc>The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8)</desc>
      <group_list>
        <group group_id="E1">
          <title>Hydromorphone</title>
          <description>Hydromorphone protocol
Hydromorphone: 0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>Usual care
Usual care: Attending administers any IV opioid in any dose he chooses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>excluding patients who were nauseated or vomiting before receiving initial IV opioids</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>excluding patients who were nauseated or vomiting before receiving initial intravenous opioid</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oxygen saturation &lt;95%</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Systolic blood pressure &lt;90 mmHg</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Chang, MD, MS</name_or_title>
      <organization>Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore Medical Center</organization>
      <phone>718-920-7464</phone>
      <email>achang@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

